drugset / Trial / NCT01790490

Glutamatergic Modulation of Cocaine-related Deficits

NCT01790490

Phase 2 Completed 8 enrolled New York State Psychiatric Institute
RandomizedCrossoverTriple-blindTreatment

Summary

Cocaine dependence involves problematic neuroadaptations, such as heightened reactivity to cocaine cues, that may be responsive to pharmacological modulation of glutamatergic circuits. Despite promising preclinical findings with n-methyl-d-aspartate receptor (NMDAr) modulators, studies with human subjects have been unsuccessful to date. The purpose of this investigation is to examine the effects of the NMDAr antagonist ketamine, recently found to have potent therapeutic effects in humans, on cue-induced craving and impaired motivation for quitting cocaine in cocaine dependent participants, 24-hours post-infusion.

Timeline

Start
2011-02
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.41 mg/kg Intravenous
Subject Ketamine Small molecule 0.71 mg/kg Intravenous
Subject Lorazepam Small molecule 2 mg Intravenous

Indications